• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Rallybio Corporation

    8/29/25 4:05:26 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RLYB alert in real time by email
    8-K
    Rallybio Corp NASDAQ false 0001739410 0001739410 2025-08-26 2025-08-26
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): August 26, 2025

     

     

    RALLYBIO CORPORATION

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   001-40693   85-1083789

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    234 Church Street, Suite 1020

    New Haven, Connecticut

      06510
    (Address of Principal Executive Offices)   (Zip Code)

    Registrant’s Telephone Number, Including Area Code: 203 859-3820

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

      ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, par value $0.0001 per share   RLYB   NASDAQ Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

    As previously disclosed by Rallybio Corporation (“the Company”), on February 24, 2025, the Company received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department notifying the Company that the closing bid price of the Company’s shares of common stock was below the minimum closing bid price of $1.00 per share during the prior 30 consecutive business days (the “Notice”), as required for continued listing on the Nasdaq. Pursuant to Nasdaq’s Listing Rules, the Company had until August 25, 2025 (the “Initial Compliance Date”) to regain compliance with the minimum closing bid price requirement. As of the Initial Compliance Date, the Company had not regained compliance with the minimum closing bid price requirement.

    On August 26, 2025, Nasdaq notified the Company that it had approved the Company’s application to transfer its listing to the Nasdaq Capital Market and that the Company is eligible for an additional 180 calendar day period, or until February 23, 2026 (the “Second Compliance Date”), to regain compliance with the minimum closing bid price requirement. At the opening of business on August 29, 2025, the Company’s common stock was transferred to the Nasdaq Capital Market, which operates in substantially the same manner as the Nasdaq Global Select Market, where it will continue to trade under the symbol “RLYB.”

    The Company intends to monitor the closing bid price for its securities and explore available options to regain compliance within the prescribed time period, including by effecting a reverse stock split, if necessary.

    In the event the Company fails to regain compliance before the Second Compliance Date, the Company will receive a written notification from Nasdaq that its common stock will be delisted. If the Company were to receive such a notification, the Company could appeal Nasdaq’s determination to delist its common stock to a Nasdaq Hearings Panel.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit No.    Description
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

          RALLYBIO CORPORATION
    Date:    August 29, 2025     By:  

    /s/ Jonathan I. Lieber

         

    Jonathan I. Lieber

    Chief Financial Officer and Treasurer

    Get the next $RLYB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RLYB

    DatePrice TargetRatingAnalyst
    4/9/2025Buy → Neutral
    H.C. Wainwright
    5/15/2024Overweight → Neutral
    JP Morgan
    2/7/2024$7.00 → $1.50Buy → Hold
    Jefferies
    4/17/2023$18.00Buy
    H.C. Wainwright
    4/10/2023$17.00Outperform
    Wedbush
    12/9/2022$21.00Overweight
    JP Morgan
    2/22/2022$32.00Mkt Outperform
    JMP Securities
    8/23/2021$40.00Outperform
    Evercore ISI Group
    More analyst ratings

    $RLYB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates

    – Data Readouts from Cohort 1 and Cohort 2 of RLYB116 Confirmatory PK/PD Study on Track for 3Q and 4Q 2025, Respectively – – Sold Interest in REV102 to Recursion Pharmaceuticals for Up to $25 Million, including an Upfront Equity Payment of $7.5 Million – – Cash Runway into Mid-2027 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported financial results for the second quarter ended June 30, 2025, and provided an update on recent company developments. "The second quarter marked a pivotal step forward as we advanced our lead program, RLYB116,

    8/7/25 8:00:00 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

    Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio's (NASDAQ:RLYB) full interest in their joint ENPP1 inhibitor program (REV102) and an associated backup molecule for the treatment of hypophosphatasia (HPP), a rare and debilitating genetic disorder. "We extend our sincere thanks to Rallybio for their invaluable partnership in advancing this program to its current stage," said David Hallett, Chief Scientific Officer of Recursion. "Having full ownership of this important program allows Recursion to accelerate the development of the first

    7/8/25 8:00:00 AM ET
    $RLYB
    $RXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

    – Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that it has entered into a definitive agreement to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for the treatment of patients with hypophosphatasia (HPP), to joint venture partner Recursion Pharmaceuticals for up to $25 million, including an upfront equity payment of $7.5 million and near term milestones. With the upf

    7/8/25 8:00:00 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLYB
    SEC Filings

    View All

    SEC Form 8-K filed by Rallybio Corporation

    8-K - Rallybio Corp (0001739410) (Filer)

    8/29/25 4:05:26 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Rallybio Corporation

    10-Q - Rallybio Corp (0001739410) (Filer)

    8/7/25 8:33:38 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rallybio Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Rallybio Corp (0001739410) (Filer)

    8/7/25 8:08:49 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLYB
    Leadership Updates

    Live Leadership Updates

    View All

    Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023

    -- Martin Mackay, Ph.D., CEO, Chairman of the Board and Co-Founder of Rallybio To Become Executive Chairman -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Stephen Uden, M.D., Rallybio's President, Chief Operating Officer and Co-Founder has been appointed to the role of Chief Executive Officer, effective August 1, 2023. Dr. Uden will remain President and will also be appointed to Rallybio's Board of Directors. The Company does not expect to hire a replacement for Dr. Uden's current role. He will succeed Mart

    6/29/23 7:00:00 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results

    -- Proof-of-Concept Achieved for RLYB212; Showed Rapid and Complete Elimination of Transfused HPA-1a Positive Platelets in HPA-1a Negative Subjects -- -- Phase 1 Multiple Dose Cohort RLYB212 Study Initiated -- -- Phase 1 Multiple Ascending Dose Study of RLYB116 Continues to Progress; Safety, PK and PD Data Expected in 4Q 2023 -- -- $169.0 million cash, cash equivalents and marketable securities as of December 31, 2022; Provides Runway into 1Q 2025 -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results

    3/6/23 8:00:00 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rallybio Announces Appointment of Jonathan I. Lieber as Chief Financial Officer

    Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Jonathan I. Lieber will join as the Company's Chief Financial Officer (CFO), effective February 1, 2023. Mr. Lieber succeeds Jeffrey Fryer, CPA, Rallybio's Co-Founder and CFO. The company announced Mr. Fryer's departure in June 2022, and following a transition period with Mr. Lieber, Mr. Fryer will depart the company on February 15, 2023. Mr. Lieber brings more than 30 years of experience as a CFO for public and private life sciences companies and an investment ban

    1/31/23 4:05:00 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLYB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Boudreau Helen M

    4 - Rallybio Corp (0001739410) (Issuer)

    5/15/25 5:10:09 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Chung Wendy

    4 - Rallybio Corp (0001739410) (Issuer)

    5/15/25 5:09:20 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hunt Ronald

    4 - Rallybio Corp (0001739410) (Issuer)

    5/15/25 5:08:25 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLYB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rallybio downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Rallybio from Buy to Neutral

    4/9/25 8:36:28 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rallybio downgraded by JP Morgan

    JP Morgan downgraded Rallybio from Overweight to Neutral

    5/15/24 7:39:44 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rallybio downgraded by Jefferies with a new price target

    Jefferies downgraded Rallybio from Buy to Hold and set a new price target of $1.50 from $7.00 previously

    2/7/24 6:42:56 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLYB
    Financials

    Live finance-specific insights

    View All

    Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

    Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio's (NASDAQ:RLYB) full interest in their joint ENPP1 inhibitor program (REV102) and an associated backup molecule for the treatment of hypophosphatasia (HPP), a rare and debilitating genetic disorder. "We extend our sincere thanks to Rallybio for their invaluable partnership in advancing this program to its current stage," said David Hallett, Chief Scientific Officer of Recursion. "Having full ownership of this important program allows Recursion to accelerate the development of the first

    7/8/25 8:00:00 AM ET
    $RLYB
    $RXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

    -- 100 mg Results Demonstrated a Mean Reduction of Greater than 93% in Free C5 with Low Volume Once-a-Week Subcutaneous Dosing -- -- Data Supports the Study of RLYB116 as a Differentiated Therapeutic for the Treatment of Generalized Myasthenia Gravis -- -- Company Announces Extension of Runway to 3Q 2025 As Part of Portfolio Prioritization -- -- Conference Call and Webcast Today at 8:30 AM Eastern Time -- Rallybio Corporation (NASDAQ:RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume subcutaneously injected inhibitor of complement component 5 (C5), in development for patients with complement-mediated disea

    12/20/23 8:00:00 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLYB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Rallybio Corporation

    SC 13G/A - Rallybio Corp (0001739410) (Subject)

    11/12/24 10:34:15 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Rallybio Corporation

    SC 13G - Rallybio Corp (0001739410) (Subject)

    7/30/24 9:06:36 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rallybio Corporation

    SC 13G/A - Rallybio Corp (0001739410) (Subject)

    7/30/24 12:47:55 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care